Troy A. Ignelzi's Insider Trades & SAST Disclosures
Troy A. Ignelzi's most recent trade in Rapport Therapeutics Inc. was a trade of 9,900 Common Stock done at an average price of $10.1 . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Troy A. Ignelzi.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | Troy A. Ignelzi | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 10.10 per share. | 12 Mar 2025 | 9,900 | 9,900 | - | 10.1 | 99,990 | Common Stock |
| Rapport Therapeutics Inc. | Troy A. Ignelzi | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.98 per share. | 12 Mar 2025 | 100 | 10,000 | - | 10.0 | 998 | Common Stock |
| Rapport Therapeutics Inc. | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 142,000 | 142,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc. | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 81,366 | 81,366 | - | - | Stock Option (Right to Buy) | |
| Contineum Therapeutics Inc... | Troy A. Ignelzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 6,350 | 6,350 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc... | Troy A. Ignelzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 23,150 | 23,150 | - | - | Stock Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2023 | 1,500 | 93,226 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 22 Aug 2023 | 1,500 | 31,987 (0%) | 0% | 9.2 | 13,800 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 174.88 per share. | 22 Aug 2023 | 855 | 31,052 (0%) | 0% | 174.9 | 149,522 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 175.59 per share. | 22 Aug 2023 | 505 | 30,547 (0%) | 0% | 175.6 | 88,673 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 173.64 per share. | 22 Aug 2023 | 80 | 31,907 (0%) | 0% | 173.6 | 13,891 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 176.60 per share. | 22 Aug 2023 | 60 | 30,487 (0%) | 0% | 176.6 | 10,596 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,000 | 94,726 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 23 May 2023 | 9,000 | 39,487 (0%) | 0% | 9.2 | 82,800 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 223.21 per share. | 23 May 2023 | 3,309 | 33,361 (0%) | 0% | 223.2 | 738,602 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 222.24 per share. | 23 May 2023 | 2,093 | 36,670 (0%) | 0% | 222.2 | 465,148 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 224.19 per share. | 23 May 2023 | 1,070 | 32,291 (0%) | 0% | 224.2 | 239,883 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 225.19 per share. | 23 May 2023 | 1,022 | 31,269 (0%) | 0% | 225.2 | 230,144 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 225.93 per share. | 23 May 2023 | 782 | 30,487 (0%) | 0% | 225.9 | 176,677 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 221.28 per share. | 23 May 2023 | 724 | 38,763 (0%) | 0% | 221.3 | 160,207 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 190.01 per share. | 21 Feb 2023 | 6,000 | 30,487 (0%) | 0% | 190.0 | 1,140,060 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 6,000 | 103,726 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 21 Feb 2023 | 6,000 | 36,487 (0%) | 0% | 9.2 | 55,200 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 17,350 | 17,350 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 8,650 | 30,487 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 817 | 109,926 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 17 Jan 2023 | 817 | 22,654 (0%) | 0% | 9.2 | 7,516 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 201.41 per share. | 17 Jan 2023 | 817 | 21,837 (0%) | 0% | 201.4 | 164,552 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 200.14 per share. | 17 Jan 2023 | 200 | 21,837 (0%) | 0% | 200.1 | 40,028 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 17 Jan 2023 | 200 | 22,037 (0%) | 0% | 9.2 | 1,840 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 200 | 109,726 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2022 | 10,869 | 110,743 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 16 Dec 2022 | 10,869 | 20,839 (0%) | 0% | 9.2 | 99,995 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 16 Dec 2022 | 627 | 21,837 (0%) | 0% | 9.2 | 5,768 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2022 | 627 | 626 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2022 | 371 | 8,559 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 16 Dec 2022 | 371 | 21,210 (0%) | 0% | 9.2 | 3,413 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 225.85 per share. | 15 Nov 2022 | 16,500 | 9,970 (0%) | 0% | 225.9 | 3,726,525 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 16,500 | 121,612 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 15 Nov 2022 | 16,500 | 26,470 (0%) | 0% | 9.2 | 151,800 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 229.77 per share. | 30 Sep 2022 | 5,189 | 14,503 (0%) | 0% | 229.8 | 1,192,277 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 228.74 per share. | 30 Sep 2022 | 2,819 | 19,692 (0%) | 0% | 228.7 | 644,818 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 227.05 per share. | 30 Sep 2022 | 2,459 | 22,511 (0%) | 0% | 227.1 | 558,316 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 231.30 per share. | 30 Sep 2022 | 2,000 | 11,470 (0%) | 0% | 231.3 | 462,600 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 232.00 per share. | 30 Sep 2022 | 1,100 | 10,370 (0%) | 0% | 232 | 255,200 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 230.02 per share. | 30 Sep 2022 | 1,000 | 13,470 (0%) | 0% | 230.0 | 230,020 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 233.20 per share. | 30 Sep 2022 | 400 | 9,970 (0%) | 0% | 233.2 | 93,280 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 230.48 per share. | 30 Sep 2022 | 33 | 14,470 (0%) | 0% | 230.5 | 7,606 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 227.83 per share. | 09 Aug 2022 | 16,500 | 24,970 (0%) | 0% | 227.8 | 3,759,195 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 16,500 | 138,112 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 09 Aug 2022 | 16,500 | 41,470 (0%) | 0% | 9.2 | 151,800 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2022 | 3,500 | 155,356 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 130.81 per share. | 19 Apr 2022 | 3,500 | 24,970 (0%) | 0% | 130.8 | 457,835 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 19 Apr 2022 | 3,500 | 28,470 (0%) | 0% | 9.2 | 32,200 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2022 | 704 | 154,652 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 133.20 per share. | 19 Apr 2022 | 704 | 24,970 (0%) | 0% | 133.2 | 93,773 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 19 Apr 2022 | 704 | 25,674 (0%) | 0% | 9.2 | 6,477 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2022 | 40 | 154,612 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 134.45 per share. | 19 Apr 2022 | 40 | 24,970 (0%) | 0% | 134.5 | 5,378 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 19 Apr 2022 | 40 | 25,010 (0%) | 0% | 9.2 | 368 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 48,500 | 48,500 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,500 | 158,856 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 111.14 per share. | 15 Feb 2022 | 1,500 | 24,970 (0%) | 0% | 111.1 | 166,710 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 15 Feb 2022 | 1,500 | 26,470 (0%) | 0% | 9.2 | 13,800 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 5,869 | 160,356 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 21 Dec 2021 | 5,869 | 23,869 (0%) | 0% | 9.2 | 53,995 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 21 Dec 2021 | 1,101 | 24,970 (0%) | 0% | 9.2 | 10,129 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 1,101 | 8,930 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 152.32 per share. | 08 Nov 2021 | 13,500 | 18,000 (0%) | 0% | 152.3 | 2,056,320 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2021 | 13,500 | 166,225 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 08 Nov 2021 | 13,500 | 31,500 (0%) | 0% | 9.2 | 124,200 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 08 Sep 2021 | 7,000 | 25,000 (0%) | 0% | 9.2 | 64,400 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 7,000 | 182,725 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.16 per share. | 08 Sep 2021 | 7,000 | 18,000 (0%) | 0% | 116.2 | 813,120 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 1,900 | 179,725 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 120.05 per share. | 08 Sep 2021 | 1,900 | 18,000 (0%) | 0% | 120.1 | 228,095 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 08 Sep 2021 | 1,900 | 19,900 (0%) | 0% | 9.2 | 17,480 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 600 | 182,125 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 121.01 per share. | 08 Sep 2021 | 600 | 18,000 (0%) | 0% | 121.0 | 72,606 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 08 Sep 2021 | 600 | 18,600 (0%) | 0% | 9.2 | 5,520 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 500 | 181,625 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 120.05 per share. | 08 Sep 2021 | 500 | 18,000 (0%) | 0% | 120.1 | 60,025 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 08 Sep 2021 | 500 | 18,500 (0%) | 0% | 9.2 | 4,600 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 5,000 | 189,725 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 20 Aug 2021 | 5,000 | 18,000 (0%) | 0% | 9.2 | 46,000 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 14 Jun 2021 | 2,248 | 15,248 (0%) | 0% | 9.2 | 20,682 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 129.45 per share. | 14 Jun 2021 | 2,248 | 13,000 (0%) | 0% | 129.5 | 291,004 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2021 | 2,248 | 10,031 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2021 | 900 | 1,605 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 132.52 per share. | 14 Jun 2021 | 900 | 13,000 (0%) | 0% | 132.5 | 119,268 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 14 Jun 2021 | 900 | 13,900 (0%) | 0% | 9.2 | 8,280 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2021 | 352 | 1,253 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 128.40 per share. | 14 Jun 2021 | 352 | 13,000 (0%) | 0% | 128.4 | 45,197 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 14 Jun 2021 | 352 | 13,352 (0%) | 0% | 9.2 | 3,238 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.07 per share. | 10 May 2021 | 7,000 | 13,000 (0%) | 0% | 110.1 | 770,490 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 10 May 2021 | 7,000 | 20,000 (0%) | 0% | 9.2 | 64,400 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 7,000 | 194,925 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 10 May 2021 | 200 | 13,000 (0%) | 0% | 120 | 24,000 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.20 per share. | 10 May 2021 | 200 | 13,200 (0%) | 0% | 9.2 | 1,840 | Common Stock |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 200 | 194,725 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 51,650 | 51,650 | - | - | Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges